CARLSBAD, Calif., Sept. 1 -- Laser Photonics Inc. announced that its Acculase Inc. subsidiary has filed with the US Food and Drug Administration for 510 (k) clearance to commercially market its excimer laser system for the treatment of dermatological disorders, including psoriasis. The company expects to launch the product in early 2000, and has engaged Healthworld Corp. to handle advertising, contract sales, consulting, medical education, public relations and marketing research.
Laser Photonics recently completed a financing to fund capital expenditures related to marketing activities and to additional clinical trials, which are being conducted at Massachusetts General Hospital. The company said its excimer laser is designed to use fiber optics to deliver UV energy precisely to lesion sites, thereby minimizing the effects of treatment on non-affected skin.

---

There are 442 suppliers of Lasers in the Photonics Marketplace.

---